Healthcare

Mesoblast Limited (ASX:MSB) develops and commercialises allogeneic cellular medicines for inflammatory diseases. Its US-approved therapy RYONCIL treats steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children. During FY26, Mesoblast (ASX:MSB) reported its first full year of commercial RYONCIL revenue while progressing studies intended to evaluate additional …

Penthrox delivers inhaled, needle-free pain relief using methoxyflurane. The company describes it as a portable, self-administered, non-opioid analgesic for acute pain. Product availability and approved uses vary across markets. For Medical Developments International (ASX:MVP), the central commercial issue is how clinical uptake translates into …

Conventional X-ray tubes use heat to release electrons. Micro-X Ltd (ASX:MX1) instead uses carbon nanotube emitters that operate as cold cathodes, controlled through electronic systems. Its technology website describes NEX as a platform combining emitters with tailored tube designs for different imaging applications. This …

Imugene Limited (ASX:IMU) describes azer-cel, also called azercabtagene zapreleucel, as an investigational allogeneic CAR T-cell therapy directed at CD19, a protein expressed by several B-cell cancers. Allogeneic means that the engineered T cells originate from donors rather than being manufactured separately from each patient’s …

The SOZO system provides a rapid assessment of fluid and tissue composition. Its L-Dex capability is used to monitor changes associated with breast cancer-related lymphoedema, a condition involving abnormal fluid accumulation that can occur following cancer treatment. The measurement approach is intended to support …

Invion Limited (ASX:IVX) is an Australian clinical-stage life sciences company developing Photosoft photodynamic therapy (PDT) technology for cancer treatment. Its lead clinical programme uses the investigational photosensitiser INV043 in patients with non-melanoma skin cancer. An April 2026 announcement detailed findings from a further patient …

In its FY26 results announcement, Mayne Pharma Group Limited (ASX:MYX) described increased investment in women’s health sales and promotional capability. The company identified menopause-related treatments as an area of commercial activity, alongside its contraception portfolio. These initiatives concern prescriber engagement and patient access.